Pediatric patients with psoriasis and psychiatric disorders: premorbidity and comorbidity in a case-control study

Kara, Tayfun; Topkarcı, Zeynep; Yılmaz, Semra; Akaltun, İsmail; Erdoğan, Bilgen

doi:10.1080/09546634.2018.1476653

Cited by 19 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In both sexes, psoriatic patients and their partners suffer from psychopathological and sexual consequences related to disease severity (66). A significant increase in psychiatric disorders occurs in pediatric psoriasis, with a 6.65-fold greater risk of depression and a 9.21-fold greater risk of anxiety, compared with the controls (67).…”

Section: Mental Health Diseasesmentioning

confidence: 99%

Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review

Ding

Zhou

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Psoriasis is a chronic autoimmune inflammatory disease that remains active for a long period, even for life in most patients. The impact of psoriasis on health is not only limited to the skin, but also influences multiple systems of the body, even mental health. With the increasing of literature on the association between psoriasis and extracutaneous systems, a better understanding of psoriasis as an autoimmune disease with systemic inflammation is created. Except for cardiometabolic diseases, gastrointestinal diseases, chronic kidney diseases, malignancy, and infections that have received much attention, the association between psoriasis and more systemic diseases, including the skin system, reproductive system, and oral and ocular systems has also been revealed, and mental health diseases draw more attention not just because of the negative mental and mood influence caused by skin lesions, but a common immune-inflammatory mechanism identified of the two systemic diseases. This review summarizes the epidemiological evidence supporting the association between psoriasis and important and/or newly reported systemic diseases in the past 5 years, and may help to comprehensively recognize the comorbidity burden related to psoriasis, further to improve the management of people with psoriasis.

show abstract

Section: Mental Health Diseasesmentioning

confidence: 99%

Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review

Ding

Zhou

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Nine studies assessed the presence of social anxiety disorder (26,(29)(30)(31)(32)(33)(34)(35)(36), 6 by interview, 3 with selfadministered questionnaires and 1 with medical records. Meta-analysis showed a high prevalence of social anxiety disorder in patients with psoriasis (15% [95% CI 9-21]) with very wide heterogeneity (I 2 =97.2%) and risk of publication bias (Egger's test, p = 0.016) (Fig.…”

Section: Social Anxiety Disordermentioning

confidence: 99%

Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysi

Jalenques

Bourlot²,

Martínez³

et al. 2022

Acta Derm Venereol

View full text Add to dashboard Cite

The magnitude of the association between psoriasis and depression has been evaluated, but not that between psoriasis and anxiety. The aim of this systematic review and meta-analysis was to examine the prevalence and odds of anxiety disorders and symptoms in patients with psoriasis. Five medical databases (Cochrane Database, EMBASE, PubMed, PsychINFO, ScienceDirect) were searched for relevant literature. A total of 101 eligible articles were identified. Meta-analysis revealed different prevalence rates depending on the type of anxiety disorder: 15% [9–21] for social anxiety disorder, 11% [9–14] for generalized anxiety disorder, and 9% [8–10] for unspecified anxiety disorder. There were insufficient studies assessing other anxiety disorders to be able to draw any conclusions on their true prevalence. Meta-analysis also showed a high prevalence of anxiety symptoms (34% [32–37]). Case-control studies showed a positive association between psoriasis and unspecified anxiety disorder (odds ratio 1.48 [1.18; 1.85]) and between psoriasis and anxiety symptoms (odds ratio 2.51 [2.02; 3.12]). All meta-analyses revealed an important heterogeneity, which could be explained in each case by methodological factors. The results of this study raise the necessity of screening for the presence of anxiety disorders, as previously recommended for depressive disorders, in patients with psoriasis and, if necessary, to refer such patients for evaluation by a mental health professional and appropriate treatment.

show abstract

“…Paediatric patients with psoriasis may also have co‐morbidities seen in adult patients such as diabetes mellitus, Crohn’s disease, obesity, ischaemic heart disease, hyperlipidaemia, dyslipidaemia, hypertension and metabolic syndrome 7–10 . Large‐scale epidemiological studies have confirmed the increased risk for psychosocial co‐morbidities like psychiatric disorder, depression and anxiety in children 11–13 . Children suffering from even mild psoriasis have a poorer quality of life (QoL) than that of their peers because of itching, fatigue and feelings of stigmatization, thereby affecting their emotional well‐being and school functioning 14 .…”

Section: Introductionmentioning

confidence: 99%

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

Bodemer

Kaszuba

Kingo

et al. 2021

Acad Dermatol Venereol

112

View full text Add to dashboard Cite

Background Secukinumab has demonstrated sustained long‐term efficacy with a favourable safety profile in various psoriatic disease manifestations in adults. Objectives Here, the efficacy and safety of two secukinumab dosing regimens [low dose (LD) and high dose (HD)] in paediatric patients with severe chronic plaque psoriasis over one year are reported. Methods In this multicentre, double‐blind study (NCT02471144), patients aged 6 to <18 years with severe chronic plaque psoriasis were stratified and randomized by weight (<25 kg, 25 to <50 kg, ≥50 kg) and age (6 to <12 years, 12 to <18 years) to receive low‐dose (LD: 75/75/150 mg) or high‐dose (HD: 75/150/300 mg) subcutaneous secukinumab or placebo or etanercept 0.8 mg/kg (up to a max of 50 mg). Results Overall, 162 patients were randomized to receive secukinumab LD (n = 40) or HD (n = 40), etanercept (n = 41) or placebo (n = 41). The co‐primary objectives of the study were met with both secukinumab doses (LD and HD) showing superior efficacy compared to placebo (P < 0.0001) with respect to PASI 75 response (80.0%, 77.5% vs. 14.6%) and IGA mod 2011, 0 or 1 response (70%, 60% vs. 4.9%) at Week 12. Both secukinumab doses were superior to placebo (P < 0.0001) with respect to PASI 90 response at Week 12 (72.5%, 67.5% vs. 2.4%). The efficacy of both doses was sustained to Week 52 with secukinumab achieving higher responses vs. etanercept (PASI 75/90/100: LD, 87.5%/75.0%/40.0% and HD, 87.5%/80.0%/47.5.% vs. etanercept, 68.3%/51.2%/22.0% and IGA 0 or 1: LD, 72.5% and HD, 75.0% vs. etanercept, 56.1%). The safety profile of secukinumab was consistent with the adult Phase 3 studies, with no new safety signals identified. Conclusions Both doses of secukinumab demonstrated high and sustained efficacy up to Week 52 with a favourable safety profile in paediatric patients with severe chronic plaque psoriasis.

show abstract

Pediatric patients with psoriasis and psychiatric disorders: premorbidity and comorbidity in a case-control study

Cited by 19 publications

References 25 publications

Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review

Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review

Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysi

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

Contact Info

Product

Resources

About